Table 2.
COVID-19 data
| Patient | 1 | 2 | 3 | 4 | 5 | 6 |
|---|---|---|---|---|---|---|
| Date of the first positive oropharyngeal/nasopharyngeal swab | 12/OCT/20 | 14/NOV/20 | 13/JAN/21 | 15/JAN/21 | 16/JAN/21 | 05/FEB/21 |
| Severity of COVID-19 | mild | moderate | mild | mild | mild | mild |
| 7-point ordinal scale for grading clinical status of COVID-19 | 1 | 3 | 1 | 1 | 2 | 1 |
| COVID-19 treatments | none | paracetamol, azitromicine, prednisolone | none | none | paracetamol | none |
| COVID-19 symptoms | none | fever, sore throat, loss of taste, loss of smell | none | none | headache, bone or joint pain, nasal congestion, loss of taste, loss of smell | none |
| Hospitalization | no | yes | no | no | no | no |
| Date of NTZ administration during COVID-19 | 26/NOV/20 | 02/DEC/20 | 14/JAN/21 | 20/JAN/21 | 27/JAN/21 | 10/FEB/21 |
| Date of the negative oropharyngeal/nasopharyngeal swab | 30/NOV/20 | 28/DEC/20 | 28/JAN/21 | 16/FEB/21 | 25/FEB/21 | 08/MAR/21 |
| COVID-19 duration (days) | 39 | 44 | 15 | 32 | 40 | 31 |
NTZ natalizumab, COVID-19 Coronavirus Disease 2019